THC for HIV/AIDS
This trial will study the effects of cannabis use and HIV on the brain and inflammation. Participants will be given the same treatment in a different order over 6 weeks to monitor safety and measure the effects of the drug.
- Neuroinflammatory Disease
- Neuroinflammatory Response
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there still available slots for those wishing to partake in this research?
"Per the information posted on clinicaltrials.gov, this research is not actively recruiting participants at present. The trial was first announced October 1st 2022 and last updated September 14th of that same year. Even though this investigation has halted recruitment for now, there are still 450 other studies seeking volunteers presently."
Has the Food and Drug Administration sanctioned THC for medicinal use?
"In our assessment, THC's safety was rated a 2 due to its Phase 2 trial status. This indicates that there is some information on the drug's security but none demonstrating effectiveness."